Meeting
2018 Gastrointestinal Cancers Symposium
Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study.
Authors
Takayuki Yoshino
National Cancer Center Hospital East, Kashiwa, Japan
Takayuki Yoshino , Radka Obermannova , Gyorgy Bodoky , Jana Prausová , Rocio Garcia-Carbonero , Tudor-Eliade Ciuleanu , Pilar Garcia Alfonso , David Craig Portnoy , Allen Lee Cohn , Eric Van Cutsem , Kentaro Yamazaki , Philip Clingan , Kei Muro , Tae Won Kim , Sameera R. Wijayawardana , Rebecca Hozak , Federico Nasroulah , Josep Tabernero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01183780
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 622)
DOI
10.1200/JCO.2018.36.4_suppl.622
Abstract #
622
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.
First Author: Tomohiro Nishina
Poster
2017 ASCO Annual Meeting
CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).
First Author: Axel Grothey
![BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAF<sup>V600E</sup> mCRC.](https://d201v5jt9ylckg.cloudfront.net/199/11943/153243/153243_poster_pv.jpg)
First Author: Sanne Huijberts
Poster
2017 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).
First Author: Masato Nakamura